- Home
- GSL vs VIR Comparison
GSL vs VIR Comparison
Compare GSL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- VIR
- Stock Information
- Founded
- GSL 2007
- VIR 2016
- Country
- GSL Greece
- VIR United States
- Employees
- GSL N/A
- VIR N/A
- Industry
- GSL Marine Transportation
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- VIR Health Care
- Exchange
- GSL Nasdaq
- VIR Nasdaq
- Market Cap
- GSL 1.0B
- VIR 859.9M
- IPO Year
- GSL 2006
- VIR 2019
- Fundamental
- Price
- GSL $30.51
- VIR $5.91
- Analyst Decision
- GSL Strong Buy
- VIR Strong Buy
- Analyst Count
- GSL 1
- VIR 11
- Target Price
- GSL $33.00
- VIR $25.73
- AVG Volume (30 Days)
- GSL 328.6K
- VIR 1.5M
- Earning Date
- GSL 11-05-2025
- VIR 11-05-2025
- Dividend Yield
- GSL 6.88%
- VIR N/A
- EPS Growth
- GSL 19.05
- VIR N/A
- EPS
- GSL 10.76
- VIR N/A
- Revenue
- GSL $730,277,000.00
- VIR $19,000,000.00
- Revenue This Year
- GSL $4.58
- VIR N/A
- Revenue Next Year
- GSL N/A
- VIR $15.25
- P/E Ratio
- GSL $2.83
- VIR N/A
- Revenue Growth
- GSL 4.04
- VIR N/A
- 52 Week Low
- GSL $17.73
- VIR $4.16
- 52 Week High
- GSL $33.08
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- GSL 60.94
- VIR 51.76
- Support Level
- GSL $27.81
- VIR $5.75
- Resistance Level
- GSL $28.96
- VIR $6.56
- Average True Range (ATR)
- GSL 0.69
- VIR 0.34
- MACD
- GSL 0.29
- VIR -0.02
- Stochastic Oscillator
- GSL 94.44
- VIR 23.76
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.